Due to this increased sample size, we were able to compare tumors from patients with rare germline TP53 P/LP variants (Li-Fraumeni Syndrome, LFS) against non-LFS tumors, stratified by the same proportion of tumor types. The gene discussed is TP53; the disease is Li-Fraumeni syndrome.